GlassScriptPhysician profile
Angeline S Rubasingham
NPI 1417323791
$731.46
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $127 · 2021: $191 · 2022: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $191.39 | 2021 | |
| Alexion Pharmaceuticals, INC. | $129.61 | 2022 | |
| Medtronic USA, INC. | $107.45 | 2019 | |
| Avanir Pharmaceuticals, INC. | $106.82 | 2019 | |
| Silk Road Medical, INC. | $106.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $53.99 | 2019 | |
| Edwards Lifesciences Corporation | $20.13 | 2020 | |
| Csl Behring | $15.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angeline Rubasingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.